Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Neurology

• Publication date

  1995-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.45.12.2173PMID 8848188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon beta in multiple sclerosis

  1996cited by this paper
• Pharmacotherapy of aphasia. A critical review.

  1994cited by this paper
• In vivo effects of glucocorticoids on IgE production.

  1994cited by this paper
• A review of study of Chinese women.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

  1993cited by this paper
• Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.

  1993cited by this paper
• Interferon β decreases T cell activation and interferon γ production in multiple sclerosis

  1993cited by this paper
• Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain

  1993cited by this paper
• Interferon beta in multiple sclerosis

  1993cited by this paper
• Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.

  1993cited by this paper
• Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis.

  1993cited by this paper
• Use of amphetamine in the treatment of aphasia

  1992cited by this paper
• An open‐label trial of bromocriptine in nonfluent aphasia

  1992cited by this paper
• Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis

  1992cited by this paper
• Activated suppressor cells inhibit synthesis of interferonγ in patients with multiple sclerosis and normal subjects

  1991cited by this paper
• A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma.

  1991cited by this paper
• IFN-induced 15-kDa protein is released from human lymphocytes and monocytes.

  1991cited by this paper
• Interfer beta augments supperssor cell function in multiple sclerosis

  1990cited by this paper
• Interferons and multiple sclerosis.

  1989cited by this paper
• Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.

  1989cited by this paper
• Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells.

  1988cited by this paper
• The role of pharmacotherapy in the treatment of aphasia: Preliminary results

  1988cited by this paper
• Exacerbations of multiple sclerosis in patients treated with gamma interferon.

  1987cited by this paper
• Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide.

  1987cited by this paper
• Tonsillectomy and Hodgkin's disease: results from companion population-based studies.

  1987cited by this paper
• ANTIBODY TITRES TO A ROUGH-MUTANT STRAIN OF ESCHERICHIA COLI IN PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION: Evidence of a Protective Effect Against Graft-versus-host Disease

  1987cited by this paper
• Exacerbations of multiple sclerosis in patients treated with gamma interferon

  1987cited by this paper
• Progress in the immunology of the mycobacterioses.

  1987cited by this paper
• Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.

  1987cited by this paper
• Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines.

  1984cited by this paper
• Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

  1984cited by this paper
• [Immunology of multiple sclerosis].

  1982cited by this paper
• Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production.

  1982cited by this paper
• Antibodies to alpha-interferon in a patient with systemic lupus erythematosus.

  1982cited by this paper
• Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity

  1979cited by this paper
• Suppressor cell function in multiple sclerosis.

  1978cited by this paper
• Interferon-induced skin reactivity in man.

  1977cited by this paper
• Prophylactic systemic antibiotics in colorectal surgery.

  1977cited by this paper

• Efeitos adversos no tratamento da Esclerose Múltipla com drogas imunomoduladoras

  2019cites this paper
• Immunomodulatory Effects of Taiwanese Neolitsea Species on Th1 and Th2 Functionality

  2017cites this paper
• Evaluating response to disease-modifying therapy in relapsing multiple sclerosis

  2015influential citation
• Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy

  2013cites this paper
• Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.

  2013cites this paper
• Immunopharmacological consequences of immune responses to therapeutic interferon beta

  2013influential citation
• Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

  2013cites this paper
• Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS

  2012cites this paper
• New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS.

  2010cites this paper
• Mitoxantrone treatment in multiple sclerosis induces TH2‐type cytokines

  2010cites this paper
• Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

  2009cites this paper
• Immunopathogenesis of multiple sclerosis

  2009cites this paper
• Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?

  2009cites this paper
• Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-β treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression

  2008cites this paper
• Interferon-β1b in multiple sclerosis

  2007cites this paper
• Inflammatory Disorders of the Nervous System. Pathogenesis, Immunology, and Clinical Management, 1st ed., Alireza Minagar, J. Steven Alexander (Eds.). Humana Press (2005), 362pp., US$155, ISBN: 1588294242

  2007cites this paper
• Interferon-β regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis

  2007cites this paper
• Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.

  2007cites this paper
• Early Relapse in Multiple Sclerosis-Associated Optic Neuritis Following the Use of Interferon b-1a in Chinese Patients

  2006cites this paper
• Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis

  2006cites this paper
• B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.

  2006cites this paper
• Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.

  2006cites this paper
• Neuroprotective Effects of Interferon-β in Multiple Sclerosis

  2005cites this paper
• Neurodegenerative markers : insights into multiple sclerosis

  2005cites this paper
• Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis.

  2005cites this paper
• 7 Neuroprotective Effects of Interferon-β in Multiple Sclerosis

  2005cites this paper
• Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.

  2004cites this paper
• Biologic role of interferon beta in multiple sclerosis

  2004cites this paper
• Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.

  2004cites this paper
• Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.

  2004cites this paper
• Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system.

  2004cites this paper
• Corticosteroids treatment.

  2004cites this paper
• Interferon beta‐1b modulates serum sVCAM‐1 levels in primary progressive multiple sclerosis

  2004cites this paper
• Effects of interferon-β on microglial functions as inflammatory and antigen presenting cells in the central nervous system

  2004cites this paper
• Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

  2003cites this paper
• Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment

  2003cites this paper
• Clinical characteristics of responders to interferon therapy for relapsing MS

  2003cites this paper
• Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis

  2003cites this paper
• Type I IFNs differentially modulate IL-12p70 production by human dendritic cells depending on the maturation status of the cells and counteract IFN-gamma-mediated signaling.

  2003cites this paper
• Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression.

  2003cites this paper
• Basic Principles of Immunotherapy for Neurologic Diseases

  2003cites this paper
• Risk of stroke in children

  2003cites this paper
• Basic principles of immunotherapy for neurologic diseases.

  2003cites this paper
• Multiple sclerosis and interferon beta-1b, past, present and future.

  2002cites this paper
• Multiple sclerosis and interferon β-1b, past, present and future

  2002cites this paper
• Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis.

  2002cites this paper
• Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management

  2002cites this paper
• The immunopathogenesis of multiple sclerosis

  2002cites this paper
• A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.

  2002cites this paper
• Interferon β-1b modulates MCP-1 expression and production in relapsing–remitting multiple sclerosis

  2002cites this paper
• Why does inflammation persist: a dominant role for the stromal microenvironment?

  2002cites this paper
• [Cellular aspect of neuroinflammation in Guillain-Barré syndrome: a key to a new therapeutic option?].

  2002cites this paper
• The immunopathogenesis of multiple sclerosis.

  2002cites this paper
• Differential mechanisms of action of interferon-β and glatiramer acetate in MS

  2002cites this paper
• Cutting Edge: Oral Type I IFN-τ Promotes a Th2 Bias and Enhances Suppression of Autoimmune Encephalomyelitis by Oral Glatiramer Acetate1

  2002cites this paper
• Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

  2002cites this paper
• Autoantibodies in Multiple Sclerosis Patients Before and During IFN-β1b Treatment: Are They Correlated with the Occurrence of Autoimmune Diseases?

  2002cites this paper
• The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b.

  2002cites this paper
• Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

  2002cites this paper
• Glucocorticoid and type 1 interferon interactions at the blood–brain barrier: relevance for drug therapies for multiple sclerosis

  2001cites this paper
• Measurement of intracellular cytokines in MS patients treated with β-interferon and association of a β-interferon induced exacerbation with increased expression of γ-interferon by monocytes

  2001cites this paper
• A prospective, open‐label treatment trial to compare the effect of IFN β‐1a (Avonex), IFNβ‐1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing‐remitting multiple sclerosis

  2001cites this paper
• [A short history of beta-interferon therapy of multiple sclerosis].

  2001cites this paper
• Liver and thyroid function and autoimmunity during interferon-&bgr;1b treatment for MS

  2001cites this paper
• Liver and thyroid function and autoimmunity during interferon- 1b treatment for MS

  2001cites this paper
• Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus

  2001cites this paper
• IFN-beta and TGF-beta differentially regulate IL-12 activity in human peripheral blood mononuclear cells.

  2001cites this paper
• Immunotherapeutic Strategies for Multiple Sclerosis

  2001cites this paper
• Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammation.

  2001cites this paper
• Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a

  2001cites this paper
• Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS

  2001cites this paper
• Measurement of intracellular cytokines in MS patients treated with beta-interferon and association of a beta-interferon induced exacerbation with increased expression of gamma-interferon by monocytes.

  2001cites this paper
• Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes

  2001cites this paper
• Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

  2000cites this paper
• Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

  2000cites this paper
• Long-term effect of IFNβ1b treatment on the spontaneous and induced expression of IL-10 and TGFβ1 in MS patients

  2000cites this paper
• T‐cell interleukin‐6 receptor binding in interferon‐β‐1b‐treated multiple sclerosis patients

  2000cites this paper
• A Role for Interferon- β in Guillain-Barré Syndrome?

  2000cites this paper
• IFN-b and TGF-b differentially regulate IL-12 activity in human peripheral blood mononuclear cells

  2000cites this paper
• A role for interferon-beta in Guillain-Barré Syndrome?

  2000cites this paper
• Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.

  2000cites this paper
• Contrasting responses to interferon β‐1b treatment in relapsing‐remitting multiple sclerosis: Does baseline interleukin‐12p35 messenger RNA predict the efficacy of treatment?

  2000cites this paper
• Managing the Adverse Effects of Interferon-β Therapy in Multiple Sclerosis

  2000cites this paper
• Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4.

  2000cites this paper
• Long-term effect of IFNbeta1b treatment on the spontaneous and induced expression of IL-10 and TGFbeta1 in MS patients.

  2000cites this paper
• Increased Production of Tumor Necrosis Factor (cid:97) , and Not of Interferon (cid:103) , Preceding Disease Activity in Patients With Multiple Sclerosis

  2000cites this paper
• Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients

  2000cites this paper
• Acute demyelinating disease after interferon β-1a treatment for multiple sclerosis

  2000cites this paper
• Regulation of the IL‐12/IL‐12R axis: a critical step in T‐helper cell differentiation and effector function

  1999cites this paper
• Interferon beta-1b treatment modulates TNFα and IFNγ spontaneous gene expression in MS

  1999cites this paper
• Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis.

  1999cites this paper
• Autoimmune events during interferon beta-1b treatment for multiple sclerosis.

  1999cites this paper
• Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis.

  1999cites this paper
• Multiple sclerosis

  1999cites this paper
• Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis.

  1999cites this paper
• Glatiramer Acetate or Interferon-β for Multiple Sclerosis?

  1999cites this paper
• Flow Cytometric Analysis of In Vitro Proinflammatory Cytokine Secretion in Peripheral Blood from Multiple Sclerosis Patients

  1999cites this paper
• Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS.

  1999cites this paper
• T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis.

  1999cites this paper
• Interferon beta-1b — the first long-term effective treatment of relapsing-remitting and secondary progressive multiple sclerosis (MS)

  1999cites this paper